MALVERN, Pa.--(BUSINESS WIRE)--Promedior, Inc. today announced that its novel fibrosis program and lead product, PRM-151, recombinant human Serum Amyloid P, are the subject of several presentations and posters this week at the Keystone Symposia conference on Fibrosis in Keystone, Colorado.
